AR122933A1 - Métodos para tratar la enfermedad cardiovascular - Google Patents

Métodos para tratar la enfermedad cardiovascular

Info

Publication number
AR122933A1
AR122933A1 ARP210101936A ARP210101936A AR122933A1 AR 122933 A1 AR122933 A1 AR 122933A1 AR P210101936 A ARP210101936 A AR P210101936A AR P210101936 A ARP210101936 A AR P210101936A AR 122933 A1 AR122933 A1 AR 122933A1
Authority
AR
Argentina
Prior art keywords
cardiovascular disease
methods
treat cardiovascular
disease
ziltivekimab
Prior art date
Application number
ARP210101936A
Other languages
English (en)
Inventor
Michael H Davidson
Rahul Kakkar
Madhav N Devalaraja
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR122933A1 publication Critical patent/AR122933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La descripción proporciona métodos para tratar la enfermedad cardiovascular, incluidos pacientes con enfermedad cardiovascular aterosclerótica y/o enfermedad renal crónica. El método comprende la administración de una cantidad terapéuticamente eficaz de ziltivekimab.
ARP210101936A 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular AR122933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063050441P 2020-07-10 2020-07-10

Publications (1)

Publication Number Publication Date
AR122933A1 true AR122933A1 (es) 2022-10-19

Family

ID=77126785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101936A AR122933A1 (es) 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular

Country Status (5)

Country Link
US (1) US20230287105A1 (es)
EP (2) EP4178673A1 (es)
AR (1) AR122933A1 (es)
TW (1) TW202216763A (es)
WO (1) WO2022008702A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2354149B1 (en) 2000-12-12 2017-08-30 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2608873C (en) 2005-05-20 2017-04-25 Ablynx Nv Single domain vhh antibodies against von willebrand factor
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
CN102387814A (zh) 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
EP2681243B1 (en) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
CN113117074A (zh) 2015-07-31 2021-07-16 米迪缪尼有限公司 用于治疗海帕西啶介导的病症的方法
WO2018144773A1 (en) 2017-02-01 2018-08-09 Yale University Treatment of diuretic resistance
US20190241650A1 (en) * 2018-01-05 2019-08-08 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression

Also Published As

Publication number Publication date
WO2022008702A1 (en) 2022-01-13
EP4309734A1 (en) 2024-01-24
TW202216763A (zh) 2022-05-01
US20230287105A1 (en) 2023-09-14
EP4178673A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
PA8849001A1 (es) Anticuerpos de c-met
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
PE20211196A1 (es) Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
AR119158A1 (es) Tratamientos de angioedema hereditario
PE20211065A1 (es) Metodo para tratar la epilepsia
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR119159A1 (es) Tratamientos de angioedema
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2022012557A (es) Metodos de tratamiento de la enfermedad renal diabetica.
ECSP22066085A (es) ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
BR112017009668A2 (pt) métodos de tratamento da ckd utilizando predictores de retenção de fluidos
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
EA201291122A1 (ru) Средство для профилактики и лечения заболеваний, которые сопровождаются болью в органах мочеиспускания
DOP2017000069A (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
EA202193276A1 (ru) Способы лечения холангиокарциномы
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol

Legal Events

Date Code Title Description
FB Suspension of granting procedure